These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 4018931)

  • 1. A simple approach to estimate the variability of individual plasma drug concentrations in patients at a standardized multiple dosing regimen.
    Barthel W
    Int J Clin Pharmacol Ther Toxicol; 1985 Jun; 23(6):305-10. PubMed ID: 4018931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic model of the adjustment of phenprocoumon (Falithrom) dosage.
    Barthel W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):838-50. PubMed ID: 6083961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Method for controlled establishment of steady-state plasma levels through multiple dosing.
    Weiss M; Förster W
    Int J Clin Pharmacol Biopharm; 1978 Mar; 16(3):102-4. PubMed ID: 649225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparison of the one-point method with other methods in predicting steady state drug concentrations in multiple dosing.
    Ritschel WA; Erni W
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):279-87. PubMed ID: 881281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of repeated plasma exchange on steady state kinetics of digoxin and digitoxin.
    Keller F; Hauff A; Schultze G; Offermann G; Reeck S; Molzahn M; Kreutz G; Vöhringer F
    Arzneimittelforschung; 1984; 34(1):83-6. PubMed ID: 6538425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Individualization of drug dosage by therapeutic monitoring in plasma and the application of pharmacokinetic principles].
    Klotz U
    J Clin Chem Clin Biochem; 1983 Nov; 21(11):649-58. PubMed ID: 6655441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New generalized equations for multiple dose kinetics by i.v. injection.
    Hajratwala BR
    Pharmazie; 1976; 31(10):731-3. PubMed ID: 1019197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using pharmacokinetics in drug therapy III: Estimating dosage regimens and blood levels using the fraction-lost method.
    Schumacher GE
    Am J Hosp Pharm; 1978 Aug; 35(8):955-8. PubMed ID: 677145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PK/PD simulations as a tool for rational design of clinical dosage regimens: an example with Fradafiban.
    Brickl R; Heinzel G; Weisenberger H; Schubert H; Rutsch W; Roth W
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):475-80. PubMed ID: 9352399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic parameters: which are necessary to define a drug substance?
    Benet LZ
    Eur J Respir Dis Suppl; 1984; 134():45-61. PubMed ID: 6586486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residence time and accumulation of drugs in the body.
    Weiss M
    Int J Clin Pharmacol Ther Toxicol; 1981 Feb; 19(2):82-5. PubMed ID: 7216555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration.
    Rohatagi S; Kan S; Derendorf H
    Pharmazie; 1997 Jul; 52(7):529-32. PubMed ID: 9266589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monitoring of therapy using drug concentration levels: Why? When? How?].
    Vozeh S
    Ther Umsch; 1990 Aug; 47(8):635-9. PubMed ID: 2218964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer-calculated kanamycin dosage regimen and monitoring.
    Ritschel WA; Banarer M; Lau-Chang EF
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):121-5. PubMed ID: 844931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
    Keller F; Czock D; Zellner D; Giehl M
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of steady-state concentrations of valproic acid as determined from single plasma concentrations after the first dose.
    May CA; Garnett WR
    Clin Pharm; 1983; 2(2):143-7. PubMed ID: 6411412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Model building in pharmacokinetics/Part V: Simulation of blood level curves following repetitive dosing and their experimental verification (author's transl)].
    Hammer R; Bozler G; Heinzel G; Koss FW
    Arzneimittelforschung; 1977; 27(4a):928-31. PubMed ID: 577860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study.
    Liao JJ
    Stat Med; 2005 Mar; 24(6):883-91. PubMed ID: 15558699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.